• Autolus Therapeutics’ third-quarter 2026 net loss narrowed 30% year-over-year to $55.1 million.
• AUCATZYL net product revenue jumped 95% year-over-year to $41.2 million, driven primarily by increasing demand.
• Gross margin rose to 57% from 55% in the second quarter, supported by manufacturing efficiencies.
• Initial progressive multiple sclerosis trial data were postponed to October 2027 to allow longer follow-up.
• Full-year 2026 AUCATZYL net product revenue is now expected to reach or exceed the prior guidance’s $150 million upper end.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autolus Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100700PRIMZONEFULLFEED9873899) on November 10, 2026, and is solely responsible for the information contained therein.